ArticleClinical, cosmetic and investigational dermatology2025
Exosomal miR-493-3p Promote the Secretion of CXCL10 by Suppressing Keratinocyte Autophagy in Vitiligo.
Article in Clinical, cosmetic and investigational dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitiligo is a dermatological disorder characterized by the destruction of melanocytes, resulting from a complex interplay of genetic, immune and environmental factors. Recent studies have highlighted the involvement of keratinocytes in the pathogenesis of vitiligo; however, the precise mechanisms underlying this process remain to be fully elucidated. This study aimed to elucidate the specific role of keratinocytes in vitiligo pathogenesis, investigate autophagic changes in lesional keratinocytes, validate miR-493-3p's regulatory effect on keratinocyte autophagy. Methods: Initially, the role of keratinocytes in vitiligo lesions were evaluated by reanalyzing single-cell transcriptome data from public databases. Subsequently, a comprehensive analysis of differentially expressed genes was conducted, focusing particularly on changes in the autophagy within keratinocytes. Finally, in vitro studies, including Western Blotting, ELISA, and immunofluorescence assays, were utilized to validate the effects of miR-493-3p on the autophagy, which are implicated in the secretory dysfunction of keratinocytes. Results: Our study revealed a reduction in the number of keratinocytes in vitiligo lesions, and autophagy was significantly enriched in both WGCNA and KEGG analyses. Additionally, we demonstrated that miR-493-3p directly inhibits the expression of LC3, leading to a decrease in autophagy. Ultimately, we confirmed that autophagy dysfunction results in an increase in CXCL10 levels in keratinocytes, which may be associated with immune-mediated damage to melanocytes. Conclusion: Our research illustrates the role of keratinocytes in vitiligo and clarifies how miR-493-3p induces secretion dysfunction in keratinocytes by modulating autophagy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.